Date: 2012-04-25
Type of information: Development agreement
Compound: Brilinta® (ticagrelor) - Angiomax® (bivalirudin) for injection - cangrelor
Company: AstraZeneca (UK) The Medicines Company (USA)
Therapeutic area: Cardiovascular diseases
Type agreement: development
commercialisation
co-promotion
Action mechanism: Brilinta® is an oral antiplatelet treatment for acute coronary syndrome. The drug is a direct-acting P2Y12 receptor antagonist in a new chemical class called cyclopentyltriazolopyrimidines (CPTPs).
Disease: acute ischaemic heart disease, acute coronary syndrome
Details: AstraZeneca and The Medicines Company have announced a global collaboration for their acute ischaemic heart disease compounds. The first part of this collaboration is a US co-promotion for AstraZeneca’s oral antiplatelet medicine Brilinta®. Under the terms of the co-promotion agreement, The Medicines Company sales force will begin supporting Brilinta® in May 2012. This will complement the AstraZeneca sales team’s promotion of Brilinta® to US hospital customers and practitioners whose patients with acute coronary syndrome (ACS) may benefit from this important therapy.
Under the terms of the global collaboration, a joint development committee and a joint commercialisation committee have been established to prepare and deliver global development and commercialisation plans related to AstraZeneca’s Brilinta® and The Medicines Company’s Angiomax (bivalirudin) for injection and cangrelor, which is in development as an acute intravenous antiplatelet agent. Implementation of these plans is subject to further agreements between both parties.
Financial terms: The agreement also outlines terms for the four-year US Brilinta® co-promotion agreement in which AstraZeneca will pay The Medicines Company $15 million per year for performing pre-agreed commercialisation activities with up to an additional $5 million per year paid if performance thresholds are met.
Latest news:
